{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-152016","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.236624+00:00","generated_at":"2026-05-18T14:44:18.305853+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tyra Biosciences doses first patient in Phase 2 study of TYRA-300 for low-grade, intermediate risk NMIBC","bullets":["SURF302 open-label Phase 2 study of TYRA-300 in FGFR3-altered low-grade IR NMIBC; up to 90 participants at US sites.","Primary endpoint: complete response rate at three months; initial CR data expected first half 2026.","Patients randomized to 50 mg QD or 60 mg QD; additional dosing cohort may be evaluated.","TYRA-300 also being studied in pediatric achondroplasia in BEACH301 Phase 2; first child dosing expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-152016","json":"https://secwatch.observer/filing/0001193125-25-152016.json","markdown":"https://secwatch.observer/filing/0001193125-25-152016.md","text":"https://secwatch.observer/filing/0001193125-25-152016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525152016/0001193125-25-152016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525152016/d11524d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T14:44:18.305853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}